Revisiting biomarker discovery by plasma proteomics.

Geyer PE, Holdt LM, Teupser D, Mann M. · 2017

Read Revisiting biomarker discovery by plasma proteomics. by Geyer PE, Holdt LM, Teupser D, Mann M. (2017) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc5615924.txt.

Introduction

Geyer and co-authors rethink blood biomarker hunting in Molecular Systems Biology. Blood tests are medicine's most common diagnostic tool. Yet good protein markers are few and often vague. New ones appear at a crawl. Mass spectrometry can now read the plasma proteome in depth.

The old plan was triangular. Small groups yielded single candidate markers. Antibody tests then checked them in large groups. Most candidates died on the way. The authors propose a rectangular plan instead. Profile the full protein pattern of large cohorts first. Then match patterns against health and disease states. The shift would change how labs build diagnostic choices. Early steps toward that practice are already visible. Readers get a strategy paper for systems medicine.

Catalog record

CREATORGeyer PE, Holdt LM, Teupser D, Mann M.
YEAR2017
COLLECTIONPAPERS
FORMATTXT
FILE SIZE77 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC5615924

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Revisiting biomarker discovery by plasma proteomics By Philipp E Geyer, Lesca M Holdt, Daniel Teupser, Matthias Mann Published in: Molecular Systems Biology DOI: 10.15252/msb.20156297 ABSTRACT Abstract Clinical analysis of blood is the most widespread diagnostic procedure in medicine, and blood biomarkers are used to categorize patients and to support treatment decisions. However, existing biomarkers are far from comprehensive and often lack specificity and new ones are being developed at a very slow rate. As described in this review, mass spectrometry (MS)‐based proteomics has become a powerful technology in biological research and it is now poised to allow the characterization of the plasma proteome in great depth. Previous “triangular strategies” aimed at discovering single biomarker candidates in small cohorts, followed by classical immunoassays in much larger validation cohorts. We propose a “rectangular” plasma proteome profiling strategy, in which the proteome patterns of large cohorts are correlated with their phenotypes in health and disease. Translating such concepts into clinical practice will require restructuring several aspects of diagnostic decision‐making, and we discuss some first steps in this direction. Keywords: biomarkers, diagnostic, mass spectrometry, plasma proteomics, systems medicine Subject Categories: Molecular Biology of Disease; Post-translational Modifications, Proteolysis & Proteomics; Systems Medicine INTRODUCTION The central and integrating role of blood in human physiology implies that it should be a universal reflection of an individual's state or phenotype. Its cellular components are erythrocytes, thrombocytes, and lymphocytes. The liquid portion is called plasma, when all components are retained, and serum, when the coagulation cascade has been activated (blood clotting). For simplicity, we will use the term “plasma” rather than “serum”, since most conclusions apply to both. Concentrations of various plasma components are routinely determined in clinical practice. These include electrolytes, small molecules, drugs, and proteins. The proteins constituting the plasma proteome can be categorized into three different classes (Fig 1A and B). The first contains abundant proteins with a functional role in blood. These include human serum albumin (HSA, roughly half of total protein mass); apolipoproteins, which have crucial roles in lipid transport and homeostasis; acute phase proteins of the innate immune response; and proteins of the coagulation cascade. The second class are tissue leakage proteins without a dedicated function in the circulation. Examples are enzymes such as aspartate aminotransferase (ASAT) and alanine aminotransferase (ALAT), which are used for the diagnosis of liver diseases, as well as low‐level, tissue‐specific isoforms of proteins such as cardiac troponins. The third class are signaling molecules like small protein hormones (for instance, insulin) and cytokines, which typically have very low abundances at steady state and are upregulated when needed. Baseline levels of the cytokine interleukin‐6 (IL‐6) are 5 pg/ml, establishing a minimum 1010‐fold dynamic range of the plasma proteome when compared to the concentration of the most abundant protein, HSA, with about 50 mg/ml. [Figure: Blood‐based laboratory testing in a clinical setting(A) Concentration range of plasma proteins with the gene names of several illustrative blood proteins (red dots). Concentrations are in serum or plasma and measured with diverse methods as retrieved from the plasma proteome database in May 2017 (http://www.plasmaproteomedatabase.org/) (Nanjappa et al, 2014). (B) Bioinformatic keyword annotation of the plasma proteome database. The blue boxplots with the 10–90% whiskers visualize the range of diverse proteins contributing to distinct functions. (C) Percentage of inpatient admissions receiving blood‐based laboratory testing. Numbers are based on 9 million tests performed in the year 2016 at the Institute of Laboratory Medicine, University Hospital Munich. (D) Percentage of outpatient admissions receiving blood‐based laboratory testing. (E) Distribution of laboratory tests based on frequency of request. Examples of test for different classes of analytes are as follows: Proteins and enzymes—liver enzymes, inflammatory proteins, tumor markers; Small molecules—electrolytes, substrates, vitamins; Cells—red, white blood cells, and platelets; Drugs—immunosuppressants, antibiotics, and drugs of abuse; Specific antibodies—autoantibodies and antibodies against infectious agents; and Nucleic acids—viruses and genetic variants.] In accepted use, “a biomarker is a defined characteristic that is measured as an indicator of normal biological processes, pathogenic processes, or a response to an exposure or intervention” (FDA‐NIH: Biomarker‐Working‐Group, 2016). For the purpose of this review, we focus specifically on protein or protein modification‐based biomarkers. In this sense, there are more than 100 FDA‐cleared or FDA‐approved clinical plasma or serum tests, mainly in the abundant, functional class (50%), followed by tissue leakage markers (25%), and the rest include receptor ligands, immunoglobulins, and aberrant secretions (Anderson, 2010). Most of these are decades old, and the current introduction rate of novel markers is less than two per year (Anderson et al, 2013). A typical test consists of an enzymatic assay or immunoassay against a single target. Clinicians interpret the results in conjunction with other patient information, based on their expert knowledge. Ratios of abundances are only employed in specific cases. Examples are the 60‐year‐old De Ritis ratio of ASAT/ALAT to differentiate between causes of liver disease (De‐Ritis et al, 1957) or the more recent sFlt‐1/PlGF ratio for diagnosis of preeclampsia (Levine et al, 2004). In contrast to enzymatic and antibody‐based methods, mass spectrometry (MS)‐based proteomics measures the highly accurate mass and fragmentation spectra of peptides derived from sequence‐specific digestion of proteins. Because the masses and sequences of these peptides are unique, proteomics is inherently specific, a constant problem with colorimetric enzyme tests and immunoassays (Wild, 2013). In principle, MS‐based proteomics can analyze all the proteins in a system—its proteome—and is in this sense unbiased and hypothesis‐free (Aebersold & Mann, 2016). Furthermore, MS methods are ideally suited to discover and quantify post‐translational modifications (PTMs) on proteins. These PTMs can also be the basis of diagnostic tests, such as HbA1c levels that serve as a readout of long‐term glucose exposure in the context of diabetes. Nevertheless, none of the routinely performed laboratory tests in plasma is based on proteins that were identified by mass‐spectrometric approaches, and in routine analysis, MS is so far only employed for measuring small molecules such as drugs and metabolites (Vogeser & Seger, 2016). Over the past years, the technology of MS‐based proteomics has dramatically improved, and it is now a mainstay of all biological research that involves proteins (Cox & Mann, 2011; Altelaar & Heck, 2012; Richards et al, 2015; Zhang et al, 2016). In particular, its performance has robustly matured into a sensitivity and dynamic range that makes it interesting for biomarker studies. This review will focus on the prospects of determining proteins in blood by mass spectrometry. We start by empirically assessing the role of proteins in clinical diagnostic today and exhaustively review the literature on previous attempts at finding biomarkers in plasma by MS‐based proteomics. So far, proteomics strategies have involved extensive investigations of few samples, to be followed up by targeted approaches in larger cohorts. We discuss how recent advances in technology now enable a new strategy in which deep proteomes are measured for many time points and participants with the prospect to find new biomarkers and biomarker panels. We believe that proteomics will become part of the instrumental routine in the clinical laboratory within the next decade and may even eliminate current technologies in the far future. THE CURRENT EXTENT OF CLINICAL PROTEIN‐BASED DIAGNOSTICS Laboratory tests of blood and body fluids aim at disease diagnosis or confirmation, risk prediction, prognosis monitoring, and evaluating treatment effectiveness. It

Read the complete text